United Therapeutics (NASDAQ:UTHR) CEO Sells $5,610,605.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Monday, March 30th. The stock was sold at an average price of $590.59, for a total value of $5,610,605.00. Following the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $23,926,572.67. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded down $1.69 during midday trading on Thursday, reaching $568.59. The company had a trading volume of 81,212 shares, compared to its average volume of 483,667. The company has a fifty day simple moving average of $502.93 and a two-hundred day simple moving average of $476.94. The firm has a market cap of $24.92 billion, a price-to-earnings ratio of 20.39, a price-to-earnings-growth ratio of 1.72 and a beta of 0.75. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $607.89.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same period in the prior year, the firm earned $6.19 earnings per share. The business’s quarterly revenue was up 7.4% on a year-over-year basis. Analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently modified their holdings of UTHR. Torren Management LLC acquired a new position in shares of United Therapeutics in the fourth quarter worth $26,000. Activest Wealth Management raised its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC boosted its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. grew its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new position in United Therapeutics in the 4th quarter worth about $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Positive Phase 3 TETON?1 Tyvaso data for idiopathic pulmonary fibrosis (IPF) — results met the key endpoint and expanded Tyvaso’s potential market beyond PAH, triggering the recent rally and giving a clear near?term commercial upside. United Therapeutics (UTHR) Is Up 11.5% After Positive IPF Phase 3 Tyvaso Data Met Key Endpoint
• Positive Sentiment: HC Wainwright raised its price target to $660 and reiterated a Buy rating (also nudged Q3 EPS higher), signaling strong analyst conviction around Tyvaso’s upside and supporting longer?term upside expectations. United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, HC Wainwright Analyst Says
• Positive Sentiment: Other major firms (Bank of America, Wells Fargo) lifted targets/ratings after the TETON news, reinforcing the bullish analyst consensus that the trial materially improves Tyvaso’s addressable market. United Therapeutics Gets Dual Target Hikes From BofA and Wells Fargo
• Neutral Sentiment: Elevated investor interest — unusual options activity and high-volume trading were reported, indicating speculative positioning that can amplify intraday moves (both up and down). United Therapeutics Target of Unusually High Options Trading (NASDAQ:UTHR)
• Neutral Sentiment: Analysts and outlets are reassessing valuation after the Tyvaso news — some pieces highlight upside potential but also note valuation has risen rapidly, prompting mixed “wait and watch” commentary. Assessing United Therapeutics (UTHR) Valuation After Positive Tyvaso Phase 3 IPF Trial Results
• Negative Sentiment: HC Wainwright trimmed near?term EPS estimates for Q1 and Q2 (small cuts from prior forecasts) even as it raised the Q3 outlook — near?term estimate downgrades can temper sentiment and provide a rationale for short?term profit taking after the run. HC Wainwright EPS estimate changes for UTHR

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. UBS Group lifted their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. HC Wainwright raised their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday. Wells Fargo & Company upped their price target on United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a research report on Tuesday. Cantor Fitzgerald increased their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Finally, TD Cowen raised their price objective on United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research report on Monday. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $586.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.